Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02000102 · ClinicalTrials.gov registry record
Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 14
- Enrollment target
NCT02000102: Completed study, sponsored by Stanford University.
NCT02000102 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02000102 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 14 participants
- Enrollment target
Study Summary
Patients with diabetic macular edema who were switched to aflibercept after having been treated with bevacizumab or ranibizumab were retrospectively reviewed to assess for visual acuity and anatomic outcomes.
Interventions
- DRUG Intravitreal Injection of Aflibercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2013-09 |
| Est. Completion | 2014-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02000102
The ClinicalTrials.gov registry entry for NCT02000102 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intravitreal Injection of Aflibercept is the first listed.
NCT02000102 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02000102 about?
NCT02000102 is a clinical study titled "Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab". Patients with diabetic macular edema who were switched to aflibercept after having been treated with bevacizumab or ranibizumab were retrospectively reviewed to assess for visual acuity and anatomic outcomes.
What is the current status of trial NCT02000102?
This trial is currently completed. The enrollment target is 14 participants. The study started on 2013-09. Estimated completion is 2014-09.
What interventions are being tested in trial NCT02000102?
The interventions under investigation include: Intravitreal Injection of Aflibercept (DRUG).
Who is sponsoring clinical trial NCT02000102?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.